Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Hormonal
  • Meningeal Neoplasms
  • Meningioma
  • Neoplasm Recurrence, Local
  • Somatostatin

abstract

  • This study provides Class IV evidence that in patients with recurrent or progressive meningioma, pasireotide LAR does not significantly increase the proportion of patients with PFS at 6 months.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4335993

Digital Object Identifier (DOI)

  • 10.1212/WNL.0000000000001153

PubMed ID

  • 25527270

Additional Document Info

start page

  • 280

end page

  • 6

volume

  • 84

number

  • 3